Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Characterizing the regulation of CD47 by RFX4 and RREB1
FY 2022-23
Summary
Radiation therapy and chemotherapy are unable to cure all types of cancer and can be very detrimental to a patient's overall health. Finding a novel drug that is targeted at specific cancers could improve patient outcomes. We have found a protein complex (CD47) that is highly expressed on multiple different cancers including colon cancer. This complex is allowing tumour cells to evade the immune system and prevent them from being destroyed. If we can limit the expression of this protein on cancer cells a patient's immune system could destroy the tumour cells.
We have done a screen that has shown that 2 proteins affect the expression of CD47. I am going to confirm these results by doing a CRISPR screen and a method called RNA interference that allows us to change the expression of targeted proteins. Once I have confirmed these results, I will conduct DEL screens to find small molecules that could act as proteolysis-targeting chimeric molecules (PROTACS). These are drugs that target these proteins for degradation.
Developing drugs that target CD47 expression provides novel therapeutic targets that can minimize off target effects that are common with chemotherapy.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
486038
Name
Van Ommen David A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterizing the regulation of CD47 by RFX4 and RREB1
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Cd47; Crispr; Del Screen; Fluorescence-Activated Cell Sorting; Protacs; Rfx4; Rna Interference; Rreb1; Therapeutic
Abstract
Radiation therapy and chemotherapy are unable to cure all types of cancer and can be very detrimental to a patient's overall health. Finding a novel drug that is targeted at specific cancers could improve patient outcomes. We have found a protein complex (CD47) that is highly expressed on multiple different cancers including colon cancer. This complex is allowing tumour cells to evade the immune system and prevent them from being destroyed. If we can limit the expression of this protein on cancer cells a patient's immune system could destroy the tumour cells.
We have done a screen that has shown that 2 proteins affect the expression of CD47. I am going to confirm these results by doing a CRISPR screen and a method called RNA interference that allows us to change the expression of targeted proteins. Once I have confirmed these results, I will conduct DEL screens to find small molecules that could act as proteolysis-targeting chimeric molecules (PROTACS). These are drugs that target these proteins for degradation.
Developing drugs that target CD47 expression provides novel therapeutic targets that can minimize off target effects that are common with chemotherapy.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Van Ommen, David A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~